Author/Authors :
Kashef Sara نويسنده , Saki Forough نويسنده Department of Pediatric Endocrinology, Student Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; , Karamizadeh Zohreh نويسنده Department of Pediatric Endocrinology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran , Ashkani Esfahani Soheil نويسنده Student Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran , Rasekhi Ahmad Reza نويسنده Department of General Surgery, Shiraz University of
Medical Sciences, Shiraz, IR Iran
Abstract :
Background It has long been reported that gonadotropin releasing
hormone (GnRH) analogs can improve final height of patients with
idiopathic precocious puberty (IPP). This study aimed at comparing 2
different doses of GnRH agonist, triptorelin, on the adult height of
girls with IPP. Methods From July 2013, sixteen girls with IPP were
randomly divided to 2 groups. The first Group received 1 intramuscular
injection of triptorelin 0.3 mg/kg of body weight on a monthly basis,
and the second group received this at months 1 to 6, 10 to 15, and 19 to
24. They did not receive triptorelin at months 7 to 9 and 16 to 18.
Results Patients in Group 1 received a total of 7.2 mg/kg of triptorelin
during a 2-year follow up while the Group 2 received 5.4 mg/kg
triptorelin or about 39.6 mg less than the other group during the same
period of follow up. No side effects were noted in Group 2 receiving
lower dose of triptorelin, yet, 2 cases with gray hair and 1 case with
mild rash were reported in the group receiving the higher dose. No
statistically significant difference was found between the 2 groups
regarding height after 2 years. Conclusions Treatment of IPP can be
performed with triptorelin doses of less than 0.3 mg/kg per month, with
the same height increment and lower side effects.
